此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Oral T7 Oral Testosterone in Man (Oral T7)

2013年12月10日 更新者:John Amory、University of Washington

Pharmacokinetics of a Novel Oral Testosterone Undecanoate Formulation With Concomitant Inhibition of 5alpha-Reductase by Finasteride

The purpose of this study is to test how the body absorbs and processes new forms of oral testosterone. Information gained during the study may help develop better forms of testosterone therapy in the future.

研究概览

详细说明

We will be using three drugs: The first, acyline, temporarily turns off the body's production of testosterone for about two weeks. Subjects will receive acyline as shots three times over a six-week drug administration period. During the time when the body's production of testosterone is turned off, we will give testosterone either by itself or with a medication called finasteride by mouth twice daily for one week to see how much is absorbed and present in the bloodstream after administration. Subjects will go through three one-week study drug exposure periods. During two of the three one-week study drug administration periods subjects will also take a second medication, finasteride, by mouth twice daily. On the last day of each one-week drug administration period, subjects will be admitted to the University of Washington General Clinical Research Center overnight for monitoring of your blood testosterone levels. There will be 3 overnight visits for this study. This study will allow us to determine the absorption of testosterone taken by mouth, and the relative impact of two different doses of oral finasteride on testosterone absorption.

研究类型

介入性

注册 (实际的)

11

阶段

  • 阶段2

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Washington
      • Seattle、Washington、美国、98195
        • University of Washington

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 50年 (成人)

接受健康志愿者

是的

有资格学习的性别

男性

描述

Inclusion Criteria:

  • Males between 18 and 50 years of age
  • In good health based on normal screening evaluation (consisting of a medical history, physical exam normal serum chemistry, hematology, and baseline hormone levels.
  • Must agree to not participate in another research drug study
  • Must agree to not donate blood
  • Must be willing to comply with the study protocol and procedures

Exclusion Criteria:

  • Men in poor general health, with abnormal blood results (clinical laboratory tests or hormone values)
  • A known history of alcohol or drug abuse
  • Participation in a long-term male contraceptive study within the past month
  • History of bleeding disorders or current use of anti-coagulants
  • History of sleep apnea
  • History of major psychiatric disorder
  • Body mass index > 37
  • Infertility
  • Hematocrit > 55 or < 30
  • PSA >4

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:交叉作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
安慰剂比较:Testosterone Undecanoate + placebo finasteride
Acyline 300mcg/kg subcutaneous on days 1, 15 and 29 + Testosterone Undecanoate (TU)200mg twice daily, orally for 7 days + placebo finasteride twice daily, orally for 7 days during one of the three intervention periods (First Intervention, Second Intervention or Third Intervention)
Acyline 300mcg/kg subcutaneous (days 1, 15 & 29) + testosterone undecanoate 200 mg, twice daily orally + finasteride placebo
其他名称:
  • propecia
Washout of 7 days between each of the 3 treatment arms
其他名称:
  • no active drugs
实验性的:Testosterone Undecanoate + Finasteride 0.5mg
Acyline 300mcg/kg subcutaneous on days 1, 15 & 29 + testosterone undecanoate 200mg, twice daily orally for 7 days + finasteride 0.5mg twice daily, orally for 7 days during one of the three intervention periods (First Intervention, Second Intervention or Third Intervention)
Acyline 300mcg/kg subcutaneous + testosterone undecanoate 200 mg, twice daily orally + finasteride 0.5mg twice daily, orally
其他名称:
  • propecia
Washout of 7 days between each of the 3 treatment arms
其他名称:
  • no active drug
实验性的:Testosterone Undecanoate + Finasteride 1mg
Acyline 300mcg/kg subcutaneous on days 1, 15 & 29 + testosterone undecanoate 200mg, twice daily orally for 7 days + finasteride 1mg twice daily, orally for 7 days during one of the three intervention periods ((First Intervention, Second Intervention or Third Intervention)
Acyline 300mcg/kg subcutaneous + testosterone undecanoate 200 mg, twice daily orally + finasteride 1mg twice daily, orally
其他名称:
  • propecia

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Maximum Testosterone Concentration
大体时间:0,1,2,4,8,and 12-hour post dose
Area under the curve of serum testosterone Pharmacokinetic measures time-weighted mean concentration calculated as area under the concentration curve (AUC) divided by time from initiation of dosing for the morning dose and corrected for differences in baseline hormone concentration.
0,1,2,4,8,and 12-hour post dose
Serum Dihydrotestosterone Concentration
大体时间:0,1,2,4,8,and 12-hour post dose
Area under the curve of serum dihydrotestosterone
0,1,2,4,8,and 12-hour post dose
Serum Estradiol Concentration
大体时间:0,1,2,4,8,and 12-hour post dose
Area under the curve of serum estradiol
0,1,2,4,8,and 12-hour post dose

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

一般刊物

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始

2009年7月1日

初级完成 (实际的)

2009年11月1日

研究完成 (实际的)

2009年12月1日

研究注册日期

首次提交

2009年2月10日

首先提交符合 QC 标准的

2009年2月10日

首次发布 (估计)

2009年2月12日

研究记录更新

最后更新发布 (估计)

2014年1月13日

上次提交的符合 QC 标准的更新

2013年12月10日

最后验证

2013年12月1日

更多信息

与本研究相关的术语

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

3
订阅